New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome
Assistance Publique - Hôpitaux de Paris
14 participants
Jun 26, 2025
OBSERVATIONAL
Conditions
Summary
The study would like to compare patient samples at different time points using state-of the art-phenotyping tools. Collection of blood samples of APDS patients undergoing PI3K inhibitor treatment will be collected when feasible according to the standard of care planning (a blood test is supposed to be performed for these patients at M0-M3-M6-M12 then each 6 months for a total period of 2 years from the beginning of the PI3K inhibitor treatment). The whole blood will be processed in order to isolate the peripheral blood mononuclear cells (PBMC) and the plasma. Serum, RNA and DNA extraction will be performed on a separate sample.
Eligibility
Inclusion Criteria12
- Group 1:
- Patients with genetic diagnosis of APDS type 1 or type 2 and planned to be treated by PI3Kδ selective inhibitor leniolisib
- Primary immunodeficient patients with new disease-causing variants in the PIK3CD gene or PIK3R1 gene
- Minimum age 12 years old
- Patients or holders of parental authority do not oppose participation in this research.
- Patients affiliated to a Health Insurance scheme or beneficiaries
- Group 2 :
- Patients with genetic diagnosis of APDS type 1 or type 2 already treated by PI3Kδ selective inhibitor leniolisib in the last 2 years
- Patients whose pre-treatment samples are available/analyzable
- Minimum age 12 years old
- Patients or holders of parental authority do not oppose participation in this research.
- patients affiliated to a Health Insurance scheme or beneficiaries
Exclusion Criteria2
- Bone marrow transplantation
- Refusal to participate to the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A maximum of 27 ml of blood collected at each visit for metabolic markers analysis
One urine sample collected at each visit for enteric virus infection research
One stool sample collected at each visit for enteric virus infection research
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06694363